CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Cash Flows from Operating Activities:
Net income	$ 58,902	$ 34,184
Non-cash items:
Depreciation and amortization	81,524	79,637
Impairment of assets	50,597	21,170
Share-based compensation expense	15,055	12,743
Deferred tax benefit	(4,747)	12,330
Provision for losses on accounts receivable and inventory	(2,246)	3,220
Gain on sale of assets	(8,083)	0
Other non-cash operating activities	1,945	1,038
Change in operating assets and liabilities:
Change in accounts receivable	13,807	(19,752)
Change in inventories	(68,251)	(11,624)
Change in other assets and other liabilities	(9,102)	(231)
Change in accounts payable and accrued expenses	(17,590)	5,928
Net cash provided by operating activities	111,811	138,643
Cash Flows from Investing Activities:
Capital expenditures	(38,112)	(105,245)
Proceeds from divestiture	9,808	0
Proceeds from sale of property, plant and equipment	16,263	2,314
Net cash used in investing activities	(12,041)	(102,931)
Cash Flows from Financing Activities:
Net increase in short-term loans	30,000	0
Term loan borrowings	0	347,780
Repayment of term loan borrowings	(8,750)	(258,103)
Share repurchases	(175,000)	(160,000)
Proceeds from employee stock purchase plan	3,368	3,254
Proceeds from exercise of stock options	7,712	9,446
Other	90	0
Net cash used in financing activities	(142,580)	(57,623)
Effect of exchange rates on cash and cash equivalents	(124)	(3,387)
Net Change in Cash and Cash Equivalents	(42,934)	(25,298)
Cash and Cash Equivalents at Beginning of Period	169,351	180,169
Cash and Cash Equivalents at End of Period	126,417	154,871
Supplemental Disclosures of Cash Flow Information:
Interest paid	10,739	9,492
Income taxes paid	9,888	6,233
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 10,705	$ 12,100